Live, attenuated respiratory syncytial virus
US9011876B2 · kind B2 · utility
6Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 3, 2009 |
| Grant date | Apr 21, 2015 |
| Priority date | — |
| Expiry date | Feb 21, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18564
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.